Case series of allergic bronchopulmonary aspergillosis treated successfully and safely with long-term mepolizumab

Soeda, Seiko; To, Masako; Kono, Yuta; Yamawaki, Satoshi; Tsuzuki, Ryuta; Katsube, Otohiro; Watanabe, Naoto; To, Yasuo

doi:10.1016/j.alit.2018.12.008

Cited by 31 publications

(36 citation statements)

References 10 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In addition, 48% were receiving or had received antifungal therapy; 106 patients (69.7%) had baseline eosinophil counts >500 cells/µL. 10 , 12 , 13 , 16 – 33 55 patients (36%) had baseline IgE serum values >1000 IU/mL. 10 – 12 , 14 , 15 , 17 – 19 , 21 , 23 – 28 , 30 – 32 , 34 , 35 …”

Section: Resultsmentioning

confidence: 99%

“…Baseline FEV1 values were reported for eight studies (30 patients). 12 , 13 , 23 – 26 , 28 , 29 In seven studies 12 , 23 – 25 , 28 , 29 including 26 patients FEV 1 was reported in liters, with a median of 1.50 L (range 0.74–2.39). In the remaining study FEV1 was reported as the percentage predicted with a median of 52% (range 26–72).…”

Section: Resultsmentioning

confidence: 99%

“… 13 Following treatment, FEV1 values were reported for 25 patients (83.3%), with a median of 1.66 L (range 0.66–3.16). 12 , 23 , 25 , 26 , 28 , 29…”

Section: Resultsmentioning

confidence: 99%

“…Baseline IgE levels were reported for 12 patients, 12 , 13 , 23 – 28 with a median of 2145 IU/mL (range 134–8327 IU/ml). Four studies including four patients described post-treatment levels, with a median of 720 IU/mL (range 298–3400), reaching a reduction of 66.5% compared to baseline with a follow-up period between 5 and 14 months.…”

Section: Resultsmentioning

confidence: 99%

See 3 more Smart Citations

Use of monoclonal antibodies for allergic bronchopulmonary aspergillosis in patients with asthma and cystic fibrosis: literature review

Eraso

Sangiovanni

Morales

et al. 2020

Ther Adv Respir Dis

View full text Add to dashboard Cite

Allergic bronchopulmonary aspergillosis (ABPA) is a hypersensitivity reaction (HR) mediated by antigens to Aspergillus fumigatus. It is estimated that 2–15% of patients with cystic fibrosis (CF) and between 1% and 5% of asthmatics develop ABPA, affecting approximately 4.8 million people worldwide. The goals of treatment are controlling inflammation, reducing the number of exacerbations and limiting the progression of lung damage. Systemic steroids are therefore used as the mainstay therapy, along with antifungal medications. However, many patients do not respond or develop side effects to treatment. In this scenario, biological drugs such as Omalizumab, Mepolizumab, Benralizumab and Dupilumab have been implemented in clinical practice, even though there is a lack of scientific evidence to support their use. We performed a literature review of the studies carried out which analyzed biologics for the management of ABPA in adult populations with asthma and CF. To our knowledge this is the first literature review that included all biologics. We included a total of 32 studies, all but one were descriptive studies, and the vast majority evaluated the use of Omalizumab. Biologics appeared to have more benefit for patients with ABPA and asthma than CF, specifically at decreasing the frequency of acute exacerbations and by having a steroid-sparing effect. Although a decrease in serum IgE level is considered a measure of therapy success, values may not decline as expected in the context of a significant clinical improvement, highlighting the importance of measuring patient-oriented outcomes. As evidence comes mainly from case series and case reports, randomized controlled trials are needed to evaluate further the safety and efficacy of biologics in ABPA. The reviews of this paper are available via the supplemental material section.

show abstract

Section: Resultsmentioning

confidence: 99%

Section: Resultsmentioning

confidence: 99%

“… 13 Following treatment, FEV1 values were reported for 25 patients (83.3%), with a median of 1.66 L (range 0.66–3.16). 12 , 23 , 25 , 26 , 28 , 29…”

Section: Resultsmentioning

confidence: 99%

Section: Resultsmentioning

confidence: 99%

See 2 more Smart Citations

Use of monoclonal antibodies for allergic bronchopulmonary aspergillosis in patients with asthma and cystic fibrosis: literature review

Eraso

Sangiovanni

Morales

et al. 2020

Ther Adv Respir Dis

View full text Add to dashboard Cite

show abstract

“…Several recent studies reported that IL‐5 signalling blockade had significant clinical effects on ABPA . IL‐5 is essential for eosinophil maturation and proliferation in the bone marrow and is important for prolonging eosinophil survival in the peripheral blood and tissue.…”

Section: Discussionmentioning

confidence: 99%

Allergic bronchopulmonary aspergillosis complicated by eosinophilic chronic rhinosinusitis successfully treated with mepolizumab

Matsumoto

Shigekusa

Matsuo

et al. 2019

Respirology Case Reports

View full text Add to dashboard Cite

A 67‐year‐old woman was admitted to our hospital because of frequent asthma attacks and refractory chronic rhinosinusitis. She was diagnosed with allergic bronchopulmonary aspergillosis (ABPA) concomitant with eosinophilic chronic rhinosinusitis (ECRS) on the basis of peripheral blood eosinophilia, precipitating antibodies against Aspergillus fumigatus, elevated total serum IgE, pulmonary infiltration, central bronchiectasis, mucoid impaction, and bilateral rhinosinusitis with nasal polyps, which showed remarkable eosinophil accumulation histologically, especially in the ethmoid sinuses. Treatment with mepolizumab, 100 mg every 4 weeks, was initiated for both the ABPA and ECRS. Consistent with the decrease in the peripheral eosinophil count, the asthma and rhinosinusitis symptoms were drastically ameliorated. Not only her airway symptoms but also her exercise tolerance and pulmonary function test results remarkably improved. Mepolizumab therapy enhanced the quality of life for this patient with intractable ABPA and ECRS.

show abstract

Allergic Bronchopulmonary Aspergillosis

Stahlbaum

Patterson²,

Strek³

2023

Orphan Lung Diseases

View full text Add to dashboard Cite

Case series of allergic bronchopulmonary aspergillosis treated successfully and safely with long-term mepolizumab

Cited by 31 publications

References 10 publications

Use of monoclonal antibodies for allergic bronchopulmonary aspergillosis in patients with asthma and cystic fibrosis: literature review

Use of monoclonal antibodies for allergic bronchopulmonary aspergillosis in patients with asthma and cystic fibrosis: literature review

Allergic bronchopulmonary aspergillosis complicated by eosinophilic chronic rhinosinusitis successfully treated with mepolizumab

Allergic Bronchopulmonary Aspergillosis

Contact Info

Product

Resources

About